Corporate Leaders
featured
Mad Money host Jim Cramer expresses the power of having confidence in your investments. "Start small," he says.
» Read MoreMore
-
Mad Money host Jim Cramer expresses the power of having confidence in your investments. "Start small," he says.
-
Procter & Gamble's stock price soared 79 percent when A.G. Lafley was CEO before, reports CNBC's Jackie DeAngelis. Bob Damon, Korn/Ferry International, and Fred Hassan, Warburg Pincus, discuss what bringing Lafley back says about the overall executive talent pool.
-
Same-store sales dropped at Abercrombie & Fitch in its first quarter. Stacey Widlitz of S.W. Retail Advisors, discusses how to play the stock now. And Sapna Maheshwari of BuzzFeed explains her claim that top execs at the retailer are concerned about its CEO's amount of power within the company.
-
Bob McDonald's resignation from Procter & Gamble was not a shock to many analysts, reports CNBC's Jackie DeAngelis. Jim Stengel, former global marketing officer for Procter & Gamble, discusses former CEO A.G. Lafley's return to the company.
-
Walter De Brouwer, Scanadu co-founder and CEO, explains his company's medical tricorder, which can monitor a person's vital signs just by holding up to their forehead for 10 seconds.
-
Outgoing Procter and Gamble CEO Bob McDonald told employees he will retire due to the "distraction" of all the attention focused on him from "several angles."
-
A.G. Lafley's return as boss at P&G will be beneficial to the company because he "knows where the bodies are buried," management expert Jeffrey Sonnenfeld tells CNBC.
-
You say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.
-
From the FOMC Minutes, to an unexpected weak report on manufacturing in China, what has changed about investing strategy? CNBC's Maria Bartiromo shares her observation.
-
The government has moved in on Aeropostale's chief marketing officer, who set up shell companies that took millions in kickbacks. CNBC's Andrea Day has the details.
-
SAN DIEGO-- Biopharmaceutical company Halozyme Therapeutics Inc. said Thursday that it has named David Ramsay as chief financial officer, replacing Kurt Gustafson. Gustafson had been an executive at Amgen Inc. before he joined Halozyme in 2009. Halozyme said he was leaving the company to pursue other opportunities.
-
May 23- The U.S. regulator of corporate auditors said on Thursday that the U.S. arm of global accounting firm Ernst& Young failed to fix quality control problems found in earlier reviews. The report from the Public Company Accounting Oversight Board is a blow for the firm, which markets itself as a global leader in audit quality.
-
You say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.
-
Don't get burned by solar stocks, says CNBC's Herb Greenberg. Pavel Molchanov, Raymond James, weighs in.
-
Jeffrey Sonnenfeld, Yale School of Management, shares his perspective on Apple's CEO Tim Cook's Senate grilling, and JPM's CEO Jamie Dimon's dual role vote.
-
You say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.
-
CNBC's Maria Bartiromo explains why she thinks the stock market's rally probably isn't over yet. (1:47)
